Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2020 Filed Dec 10, 2020 00:05 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 20,256 | $50.88 | $1,030,625.28 |
DisclosureSEC source: 0001209191-20-062612 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $50.35 to 51.325, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 00:05 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 30,000 | $6.32 | $189,600.00 |
DisclosureSEC source: 0001209191-20-062612 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:05 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-062613 · doc4.xml · derivative · entry 5 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,250 Underlying: Common Stock · 6,250 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:05 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 2,470 | $51.26 | $126,612.20 |
DisclosureSEC source: 0001209191-20-062613 · doc4.xml · nonDerivative · entry 4 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $50.63 to 51.50, inclusive. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:05 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 3,000 | $50.14 | $150,420.00 |
DisclosureSEC source: 0001209191-20-062613 · doc4.xml · nonDerivative · entry 3 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,470 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.63 to 50.56, inclusive. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:05 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 780 | $48.79 | $38,056.20 |
DisclosureSEC source: 0001209191-20-062613 · doc4.xml · nonDerivative · entry 2 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,470 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.05 to 48.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:05 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionCommon Stock | 6,250 | $7.80 | $48,750.00 |
DisclosureSEC source: 0001209191-20-062613 · doc4.xml · nonDerivative · entry 1 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock (Right to Buy) · Derivative | 1,562 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-20-061326 · doc4.xml · derivative · entry 8 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,063 Underlying: Common Stock · 1,562 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-061326 · doc4.xml · derivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,292 Underlying: Common Stock · 2,604 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-061326 · doc4.xml · derivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,646 Underlying: Common Stock · 2,604 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 3,693 | $49.43 | $182,544.99 |
DisclosureSEC source: 0001209191-20-061326 · doc4.xml · nonDerivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.82 to 49.69, inclusive. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 3,077 | $48.20 | $148,311.40 |
DisclosureSEC source: 0001209191-20-061326 · doc4.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.76 to 48.70, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 1,562 | $7.27 | $11,355.74 |
DisclosureSEC source: 0001209191-20-061326 · doc4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-20-061326 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-20-061326 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,771 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-060395 · doc4.xml · derivative · entry 6 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,334 Underlying: Common Stock · 1,771 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,109 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-060395 · doc4.xml · derivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,926 Underlying: Common Stock · 1,109 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 2,857 | $46.31 | $132,307.67 |
DisclosureSEC source: 0001209191-20-060395 · doc4.xml · nonDerivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.02 to 46.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 23 | $45.69 | $1,050.87 |
DisclosureSEC source: 0001209191-20-060395 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,157 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,771 | $6.55 | $11,600.05 |
DisclosureSEC source: 0001209191-20-060395 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,109 | $7.80 | $8,650.20 |
DisclosureSEC source: 0001209191-20-060395 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,680 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · derivative · entry 15 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,560 Underlying: Common Stock · 16,680 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F11 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 900 | $48.54 | $43,686.00 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 12 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F10 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.45 to 48.63, inclusive. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 4,360 | $47.75 | $208,190.00 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 11 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779,080 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F9 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.36 to 48.13, inclusive. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 3,773 | $46.69 | $176,161.37 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 10 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,783,440 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.14 to 47.08, inclusive. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 7,647 | $45.60 | $348,703.20 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 9 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,787,213 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.11 to 46.10, inclusive. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 16,680 | $0.33 | $5,504.40 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 8 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 11:05 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 416 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001209191-20-059855 · doc4.xml · derivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,084 Underlying: Common Stock · 416 shares Expires 2027-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 11:05 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 416 | $48.86 | $20,325.76 |
DisclosureSEC source: 0001209191-20-059855 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 11:05 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 416 | $6.27 | $2,608.32 |
DisclosureSEC source: 0001209191-20-059855 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,680 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · derivative · entry 14 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,240 Underlying: Common Stock · 16,680 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F11 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 13,480 | $48.52 | $654,049.60 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 7 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.00 to 48.92, inclusive. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 2,000 | $47.64 | $95,280.00 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791,660 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.22 to 47.97, inclusive. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,200 | $46.68 | $56,016.00 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,793,660 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.08 to 46.97, inclusive. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 16,680 | $0.33 | $5,504.40 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,680 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · derivative · entry 13 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,920 Underlying: Common Stock · 16,680 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F11 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 5,633 | $46.68 | $262,948.44 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.29 to 47.12, inclusive. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 11,047 | $45.84 | $506,394.48 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,783,813 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.29 to 46.28, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 16,680 | $0.33 | $5,504.40 |
DisclosureSEC source: 0001209191-20-059558 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 2,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-059292 · doc4.xml · derivative · entry 5 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,000 Underlying: Common Stock · 2,000 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
LO FRANCISChief People Officer
|
SaleCommon Stock | 304 | $48.32 | $14,689.28 |
DisclosureSEC source: 0001209191-20-059292 · doc4.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.00 to 48.50, inclusive. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
LO FRANCISChief People Officer
|
SaleCommon Stock | 1,696 | $47.56 | $80,661.76 |
DisclosureSEC source: 0001209191-20-059292 · doc4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.10 to 47.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionCommon Stock | 2,000 | $7.80 | $15,600.00 |
DisclosureSEC source: 0001209191-20-059292 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-059291 · doc4.xml · derivative · entry 4 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 6,000 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 979 | $48.30 | $47,285.70 |
DisclosureSEC source: 0001209191-20-059291 · doc4.xml · nonDerivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.00 to 48.50, inclusive. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 5,021 | $47.57 | $238,848.97 |
DisclosureSEC source: 0001209191-20-059291 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 979 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.05 to 47.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 6,000 | $7.80 | $46,800.00 |
DisclosureSEC source: 0001209191-20-059291 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-20-059290 · doc4.xml · derivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Stock · 2,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 223 | $48.41 | $10,795.43 |
DisclosureSEC source: 0001209191-20-059290 · doc4.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.40 to 48.50, inclusive. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 02:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 1,777 | $47.60 | $84,585.20 |
DisclosureSEC source: 0001209191-20-059290 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.31 to $48.115, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.